Teva’s ecopipam reaches FDA Priority Review after positive Phase 3 Tourette data
FDA grants Priority Review to Teva’s ecopipam after Phase 3 data showed a 53% lower Tourette relapse risk. See what the 2027 decision could mean.
Pharma & Biotech
Pharma & Biotech
Emalex Biosciences advances Tourette syndrome strategy as ecopipam delays relapse in Phase 3 trial
D1 receptor targeting may change Tourette syndrome care. Ecopipam’s Phase 3 data now face the bigger test: regulation and adoption.